Welcome to the 6th RNAi-Based Therapeutics Summit!
Accelerating the Clinical Approval of the Next Wave of RNAi Medicines
As innovative drug delivery platforms beyond GalNac continue to emerge and novel chemical modifications are discovered, the potential for RNAi therapeutics to treat a plethora of diseases grows. Now more than ever, RNAi therapies hold promise to treat diseases beyond the liver and provide efficacious, tolerable treatment options for patients.
The 6th RNAi-Based Therapeutics Summit is returning to Boston to showcase the latest delivery technologies, data from clinically successful extra-hepatic targeting, cutting-edge AI tools to assist payload design, and breakthrough chemical modifications which enhance stability, allowing for precise therapeutic delivery.
Uniting 70+ leaders of the RNAi world, this Summit will empower experts to pioneer their RNAi candidates into clinically successful therapies. Bringing together technical and strategic experts from Novo Nordisk, Alynlam, Switch Therapeutics, Aro Biotherapeutics, Novartis, Comanche Biopharma and more, this meeting is a unique gathering of RNAi’s sharpest minds, dedicated to progressing the next wave of RNAi therapeutics to improve healthcare for patients in need.
DOWNLOAD THE BROCHURE
What's in store for 2024?
New Data on Exciting Extra-Hepatic Targets including insights from Comanche Biopharma on placental targeting, RNAi therapy to assist cell migration and wound repair from MicroCures, and clinical data from Novo Nordisk on immune cell targeting with RNAi-lipid conjugates
Fresh Insights & A New Expert Speaker Faculty made up of leaders from R&D, translation and manufacturing, including brand new companies like ProteinQure, Avidity Biosciences and SanegeneBio speaking for the first time. All Speakers will be sharing brand new data or updates on their RNAi candidates
A New Focus on Securing Investment and Attracting Industry Partnerships to maximize the success of early-stage RNAi assets and platforms, with expertise from Sunrise Bioventures and Broadview Ventures. Ask the questions you need answering to transform your research into clinical success.
Our Expert Speakers:
Adam Dinerman
Senior Vice President & Head of Chemistry, Manufacturing & Controls
Aro Biotherapeutics
Muthiah (Mano) Manoharan
Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist
Alnylam Pharmaceuticals
Attendee Snapshot
Our 2025 Partners
What Do Your Peers Have to Say?
